Currenc Group, Inc. (CURR)
USD 1.41
(-0.28%)
USD 1.41
(-0.28%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 141.49 Million USD | 1964.35% |
| 2022 | 6.85 Million USD | -83.11% |
| 2021 | 40.57 Million USD | -12.48% |
| 2020 | 46.35 Million USD | 42.82% |
| 2019 | 32.46 Million USD | 855.81% |
| 2018 | 3.39 Million USD | 61.73% |
| 2017 | 2.09 Million USD | -25.93% |
| 2016 | 2.83 Million USD | 55.59% |
| 2015 | 1.82 Million USD | -2.28% |
| 2014 | 1.86 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.03 Million USD | -99.2% |
| 2024 Q1 | 128.44 Million USD | 0.0% |
| 2023 FY | 141.49 Million USD | 1964.35% |
| 2023 Q3 | 2.82 Million USD | -23.98% |
| 2023 Q4 | - USD | -100.0% |
| 2023 Q1 | 5.19 Million USD | -24.18% |
| 2023 Q2 | 3.71 Million USD | -28.59% |
| 2022 Q2 | 29.31 Million USD | -21.45% |
| 2022 Q4 | 6.85 Million USD | -54.2% |
| 2022 FY | 6.85 Million USD | -83.11% |
| 2022 Q1 | 37.32 Million USD | -8.01% |
| 2022 Q3 | 14.96 Million USD | -48.96% |
| 2021 Q1 | 44.18 Million USD | -4.7% |
| 2021 FY | 40.57 Million USD | -12.48% |
| 2021 Q4 | 40.57 Million USD | -3.12% |
| 2021 Q3 | 41.87 Million USD | -5.75% |
| 2021 Q2 | 44.43 Million USD | 0.57% |
| 2020 FY | 46.35 Million USD | 42.82% |
| 2020 Q2 | 30.15 Million USD | -0.84% |
| 2020 Q1 | 30.41 Million USD | -6.31% |
| 2020 Q3 | 30.06 Million USD | -0.3% |
| 2020 Q4 | 46.35 Million USD | 54.19% |
| 2019 Q4 | 32.46 Million USD | -4.61% |
| 2019 Q2 | 35.34 Million USD | 566.74% |
| 2019 FY | 32.46 Million USD | 855.81% |
| 2019 Q1 | 5.3 Million USD | 56.11% |
| 2019 Q3 | 34.02 Million USD | -3.73% |
| 2018 Q1 | 3.87 Million USD | 84.64% |
| 2018 FY | 3.39 Million USD | 61.73% |
| 2018 Q4 | 3.39 Million USD | 11.93% |
| 2018 Q3 | 3.03 Million USD | 1.93% |
| 2018 Q2 | 2.97 Million USD | -23.22% |
| 2017 Q4 | 2.09 Million USD | -31.99% |
| 2017 Q3 | 3.08 Million USD | -10.22% |
| 2017 Q2 | 3.43 Million USD | 28.54% |
| 2017 Q1 | 2.67 Million USD | -5.79% |
| 2017 FY | 2.09 Million USD | -25.93% |
| 2016 Q3 | - USD | -100.0% |
| 2016 FY | 2.83 Million USD | 55.59% |
| 2016 Q2 | 10.4 Thousand USD | -25.62% |
| 2016 Q1 | 13.98 Thousand USD | -5.89% |
| 2016 Q4 | 2.84 Million USD | 0.0% |
| 2015 Q4 | 14.85 Thousand USD | -38.55% |
| 2015 FY | 1.82 Million USD | -2.28% |
| 2015 Q3 | 24.17 Thousand USD | 0.0% |
| 2014 FY | 1.86 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 84.356% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -146.422% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 87.624% |
| Cosmos Health Inc. | 66.29 Million USD | -113.424% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -968.051% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 31.247% |
| Cronos Group Inc. | 1.13 Billion USD | 87.526% |
| Incannex Healthcare Limited | 17.04 Million USD | -730.002% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -152.892% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 48.305% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -1576.782% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -417.39% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -417.39% |
| SCYNEXIS, Inc. | 128.41 Million USD | -10.185% |
| Safety Shot Inc | 12.7 Million USD | -1013.293% |
| Theratechnologies Inc. | 77.76 Million USD | -81.937% |
| Alpha Teknova, Inc. | 128.58 Million USD | -10.035% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -165.525% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 91.013% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -850.047% |
| Dynavax Technologies Corporation | 997.09 Million USD | 85.81% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 69.964% |
| Radius Health, Inc. | 1.71 Billion USD | 91.754% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -511.796% |
| Alvotech | 950.09 Million USD | 85.108% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 80.572% |
| SIGA Technologies, Inc. | 254.83 Million USD | 44.478% |
| Shineco, Inc. | 84.17 Million USD | -68.082% |
| Silver Spike Investment Corp. | 88.57 Million USD | -59.739% |
| Journey Medical Corporation | 76.84 Million USD | -84.115% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -318.663% |
| Embecta Corp. | 1.21 Billion USD | 88.349% |
| Harrow Health, Inc. | 311.75 Million USD | 54.615% |
| Procaps Group, S.A. | 460.18 Million USD | 69.254% |
| Biofrontera Inc. | 27.93 Million USD | -406.553% |
| DURECT Corporation | 45.18 Million USD | -213.108% |
| PainReform Ltd. | 9.93 Million USD | -1324.878% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 89.958% |
| OptiNose, Inc. | 107.72 Million USD | -31.339% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -513.918% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 69.243% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -73.022% |
| ProPhase Labs, Inc. | 91.92 Million USD | -53.916% |
| Phibro Animal Health Corporation | 982.18 Million USD | 85.594% |
| Procaps Group S.A. | 460.18 Million USD | 69.254% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -226.7% |
| Viatris Inc. | 47.68 Billion USD | 99.703% |
| Rockwell Medical, Inc. | 52.17 Million USD | -171.195% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -19.811% |
| Tilray Brands, Inc. | 4.33 Billion USD | 96.736% |
| PetIQ, Inc. | 868.22 Million USD | 83.704% |
| Talphera, Inc. | 20.39 Million USD | -593.751% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 95.648% |
| Alimera Sciences, Inc. | 153.52 Million USD | 7.838% |
| Assertio Holdings, Inc. | 286.41 Million USD | 50.6% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -2277.297% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 45.815% |
| Hempacco Co., Inc. | 18.04 Million USD | -684.181% |
| Alvotech | 950.09 Million USD | 85.108% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 91.431% |
| Kamada Ltd. | 351.96 Million USD | 59.8% |
| Indivior PLC | 1.95 Billion USD | 92.749% |
| Evoke Pharma, Inc. | 7.06 Million USD | -1901.691% |
| Flora Growth Corp. | 23.62 Million USD | -498.876% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -968.051% |
| Evolus, Inc. | 188.99 Million USD | 25.137% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 88.944% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 90.648% |
| Akanda Corp. | 8.83 Million USD | -1500.572% |